Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Stadtmauer

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Blood|March 9, 1999
Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myelomaR Vescio, G Schiller, A K Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trialA K Stewart, R Vescio, G Schiller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2009
Third consensus on medical treatment of metastatic breast cancerS Beslija, J Bonneterre, H J Burstein, et al.
Bone Marrow Transplantation|February 16, 2000
Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patientsR A Vescio, C H Wu, L Zheng, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 13, 2006
Second consensus on medical treatment of metastatic breast cancerS Beslija, J Bonneterre, H Burstein, et al.
Leukemia|May 15, 2013
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 studyA J Jakubowiak, D S Siegel, T Martin, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Blood|March 9, 1999
Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myelomaR Vescio, G Schiller, A K Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trialA K Stewart, R Vescio, G Schiller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2009
Third consensus on medical treatment of metastatic breast cancerS Beslija, J Bonneterre, H J Burstein, et al.
Bone Marrow Transplantation|February 16, 2000
Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patientsR A Vescio, C H Wu, L Zheng, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 13, 2006
Second consensus on medical treatment of metastatic breast cancerS Beslija, J Bonneterre, H Burstein, et al.
Leukemia|May 15, 2013
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 studyA J Jakubowiak, D S Siegel, T Martin, et al.
Pageof 2